Cargando…

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone

BACKGROUND: Denosumab has been shown to reduce tumor size and progression, reform mineralized bone, and increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment of tumors in bone is challenging. The study objective was to assess tumor respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Engellau, Jacob, Seeger, Leanne, Grimer, Robert, Henshaw, Robert, Gelderblom, Hans, Choy, Edwin, Chawla, Sant, Reichardt, Peter, O’Neal, Michael, Feng, Amy, Jacobs, Ira, Roberts, Zachary J., Braun, Ada, Bach, Bruce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146657/
https://www.ncbi.nlm.nih.gov/pubmed/30231890
http://dx.doi.org/10.1186/s12957-018-1478-3
_version_ 1783356442575634432
author Engellau, Jacob
Seeger, Leanne
Grimer, Robert
Henshaw, Robert
Gelderblom, Hans
Choy, Edwin
Chawla, Sant
Reichardt, Peter
O’Neal, Michael
Feng, Amy
Jacobs, Ira
Roberts, Zachary J.
Braun, Ada
Bach, Bruce A.
author_facet Engellau, Jacob
Seeger, Leanne
Grimer, Robert
Henshaw, Robert
Gelderblom, Hans
Choy, Edwin
Chawla, Sant
Reichardt, Peter
O’Neal, Michael
Feng, Amy
Jacobs, Ira
Roberts, Zachary J.
Braun, Ada
Bach, Bruce A.
author_sort Engellau, Jacob
collection PubMed
description BACKGROUND: Denosumab has been shown to reduce tumor size and progression, reform mineralized bone, and increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment of tumors in bone is challenging. The study objective was to assess tumor response to denosumab using three different imaging parameters in a prespecified analysis in patients with GCTB from two phase 2 studies. METHODS: The studies enrolled adults and adolescents (skeletally mature and at least 12 years of age) with radiographically measurable GCTB that were given denosumab 120 mg every 4 weeks, with additional doses on days 8 and 15 of cycle 1. The proportion of patients with an objective tumor response was assessed using either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST), European Organisation for Research and Treatment of Cancer response criteria (positron emission tomography [PET] scan criteria), or inverse Choi density/size (ICDS) criteria. Target lesions were measured by computed tomography or magnetic resonance imaging (both studies), PET (study 2 only), or plain film radiograph (study 2 only). RESULTS: Most patients (71.6%) had an objective tumor response by at least one response criteria. Per RECIST, 25.1% of patients had a response; per PET scan criteria, 96.2% had a response; per ICDS, 76.1% had a response. 68.5% had an objective tumor response ≥ 24 weeks. Using any criteria, crude incidence of response ranged from 56% (vertebrae/skull) to 91% (lung/soft tissue), and 98.2% had tumor control ≥ 24 weeks. Reduced PET avidity appeared to be an early sign of response to denosumab treatment. CONCLUSION: Modified PET scan criteria and ICDS criteria indicate that most patients show responses and higher benefit rates than modified RECIST, and therefore may be useful for early assessment of response to denosumab. TRIAL REGISTRATION: ClinicalTrials.gov Clinical Trials Registry NCT00396279 (retrospectively registered November 6, 2006) and NCT00680992 (retrospectively registered May 20, 2008). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12957-018-1478-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6146657
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61466572018-09-24 Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone Engellau, Jacob Seeger, Leanne Grimer, Robert Henshaw, Robert Gelderblom, Hans Choy, Edwin Chawla, Sant Reichardt, Peter O’Neal, Michael Feng, Amy Jacobs, Ira Roberts, Zachary J. Braun, Ada Bach, Bruce A. World J Surg Oncol Research BACKGROUND: Denosumab has been shown to reduce tumor size and progression, reform mineralized bone, and increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment of tumors in bone is challenging. The study objective was to assess tumor response to denosumab using three different imaging parameters in a prespecified analysis in patients with GCTB from two phase 2 studies. METHODS: The studies enrolled adults and adolescents (skeletally mature and at least 12 years of age) with radiographically measurable GCTB that were given denosumab 120 mg every 4 weeks, with additional doses on days 8 and 15 of cycle 1. The proportion of patients with an objective tumor response was assessed using either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST), European Organisation for Research and Treatment of Cancer response criteria (positron emission tomography [PET] scan criteria), or inverse Choi density/size (ICDS) criteria. Target lesions were measured by computed tomography or magnetic resonance imaging (both studies), PET (study 2 only), or plain film radiograph (study 2 only). RESULTS: Most patients (71.6%) had an objective tumor response by at least one response criteria. Per RECIST, 25.1% of patients had a response; per PET scan criteria, 96.2% had a response; per ICDS, 76.1% had a response. 68.5% had an objective tumor response ≥ 24 weeks. Using any criteria, crude incidence of response ranged from 56% (vertebrae/skull) to 91% (lung/soft tissue), and 98.2% had tumor control ≥ 24 weeks. Reduced PET avidity appeared to be an early sign of response to denosumab treatment. CONCLUSION: Modified PET scan criteria and ICDS criteria indicate that most patients show responses and higher benefit rates than modified RECIST, and therefore may be useful for early assessment of response to denosumab. TRIAL REGISTRATION: ClinicalTrials.gov Clinical Trials Registry NCT00396279 (retrospectively registered November 6, 2006) and NCT00680992 (retrospectively registered May 20, 2008). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12957-018-1478-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-09-19 /pmc/articles/PMC6146657/ /pubmed/30231890 http://dx.doi.org/10.1186/s12957-018-1478-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Engellau, Jacob
Seeger, Leanne
Grimer, Robert
Henshaw, Robert
Gelderblom, Hans
Choy, Edwin
Chawla, Sant
Reichardt, Peter
O’Neal, Michael
Feng, Amy
Jacobs, Ira
Roberts, Zachary J.
Braun, Ada
Bach, Bruce A.
Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title_full Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title_fullStr Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title_full_unstemmed Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title_short Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
title_sort assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146657/
https://www.ncbi.nlm.nih.gov/pubmed/30231890
http://dx.doi.org/10.1186/s12957-018-1478-3
work_keys_str_mv AT engellaujacob assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT seegerleanne assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT grimerrobert assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT henshawrobert assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT gelderblomhans assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT choyedwin assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT chawlasant assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT reichardtpeter assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT onealmichael assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT fengamy assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT jacobsira assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT robertszacharyj assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT braunada assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone
AT bachbrucea assessmentofdenosumabtreatmenteffectsandimagingresponseinpatientswithgiantcelltumorofbone